BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at BioCentury's NewsMakers in the Biotech Industry conference in New York City on Thursday, September 7, 2006 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, www.BMRN.com . A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

  Contacts:

  Investors                           Media
  Joshua A. Grass                     Susan Ferris
  BioMarin Pharmaceutical Inc.        BioMarin Pharmaceutical Inc.
  415-506-6777                        415-506-6701

SOURCE: BioMarin Phamaceutical Inc.